Dose emission and aerodynamic characterization of the terbutaline sulphate dose emitted from a Turbuhaler at low inhalation flow

References

• Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates. Respir Med 2003;97:181–187.
   PubMed Web of Science ®Google Scholar
• Tarsin W, Assi KH, Chrystyn H. In-vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler. J Aerosol Med 2004;17:25–32.
   PubMedGoogle Scholar
• Weda M, Zanen P, de Boer AH, Barends DM, Frijlink HW. An investigation into the predictive value of cascade impactor results for side effects of inhaled salbutamol. Int J Pharm 2004;287:79–87.
   PubMed Web of Science ®Google Scholar
• Newman SP, Moren F, Trofast E, Talaee N, Clarke SW. Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. Int J Pharm. 1991;74(2-3):209–13.
   Google Scholar
• Borgström L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996;153:1636–1640.
   PubMed Web of Science ®Google Scholar
• Ross DL, Schultz RK. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. J Aerosol Med 1996;9:215–226.
   PubMedGoogle Scholar
• Assi KH, Chrystyn H. The different resistance of dry powder inhalers (DPIs). Am J Respir Crit Care Med 2001;163:A443.
   PubMedGoogle Scholar
• Hawksworth GM, James L, Chrystyn H. Characterization of the inspiratory manoeuvre when asthmatics inhale through a Turbohaler pre- and post-counselling in a community pharmacy. Respir Med 2000;94:501–504.
   PubMed Web of Science ®Google Scholar
• Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990;65:308–310.
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A et al.; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449–456.
   PubMed Web of Science ®Google Scholar
• British Pharmacopoeia. Preparations for inhalation. Aerodynamic assessment of fine particles-fine particle dose and particle size distribution (Ph. Eur. method 2.9.18). In: Stationery Office, editor. British Pharmacopoeia. London 2005. p. A277-90.
   Google Scholar
• United States Pharmacopeia. Aerosols, nasal sprays, metered dose inhalers and dry powder inhalers. The United States pharmacopeia 28 [and] The national formulary 23: The board of trustees; 2005. p. 2359–2377.
   Google Scholar
• European Pharmacopeia. 2.9.18.: Preparations for inhalation: aerodynamic assessment of fine particles.: Strasbourg, France; 2002. p. 209–217.
   Google Scholar
• Nadarassan DK, Assi KH, Chrystyn H. Aerodynamic characteristics of a dry powder inhaler at low inhalation flows using a mixing inlet with an Andersen Cascade Impactor. Eur J Pharm Sci 2010;39:348–354.
   PubMedGoogle Scholar
• Van Oort M. In vitro testing of dry powder inhalers. Aerosol Sci Technol 1995;22:364–73.
   Web of Science ®Google Scholar
• Palander A, Mattila T, Karhu M, Muttonen E. In vitro comparison of three salbutamol-containing multidose dry powder inhalers: Buventol Easyhaler®, Inspiryl Turbuhaler® and Ventoline Diskus®. Clin Drug Investig 2000;20:25–33.
   Web of Science ®Google Scholar
• Brown PH, Ning AC, Greening AP, McLean A, Crompton GK. Peak inspiratory flow through Turbuhaler in acute asthma. Eur Respir J 1995;8:1940–1941.
   PubMed Web of Science ®Google Scholar
• van der Palen J. Peak inspiratory flow through diskus and turbuhaler, measured by means of a peak inspiratory flow meter (In-Check DIAL). Respir Med 2003;97:285–289.
   PubMed Web of Science ®Google Scholar
• Broeders ME, Molema J, Hop WC, Folgering HT. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. J Aerosol Med 2003;16:131–141.
   PubMedGoogle Scholar
• Tarsin W, Corrado OJ, Brownlee K, et al. Inter-individual variability of peak inhalation rate through different inhalers by asthmatic children and adults and those with COPD. Eur Respir J 2001;18:P900 (133S).
   Google Scholar
• Abdelrahim ME. Emitted dose and lung deposition of inhaled terbutaline from Turbuhaler at different conditions. Respir Med 2010;104:682–689.
   PubMed Web of Science ®Google Scholar
• Borgström L, Bondesson E, Morén F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994;7:69–73.
   PubMed Web of Science ®Google Scholar
• Hill LS, Slater AL. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir Med 1998;92:105–110.
   PubMed Web of Science ®Google Scholar
• Prime D, Grant AC, Slater AL, Woodhouse RN. A critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol: pressurized metered dose inhaler, Diskus inhaler, Diskhaler inhaler, and Turbuhaler inhaler. J Aerosol Med 1999;12:75–84.
   PubMedGoogle Scholar
• Meakin BJ, Cainey JM, Woodcock PM. Simulated ‘in-use’ and ‘mis-use’ aspects of the delivery of terbutaline sulphate from Bricanyl TurbohalerTM dry powder inhalers. Int J Pharm. 1995;119:103–8(2).
   Google Scholar
• Meakin BJ, Cainey JM, Woodcock PM. Drug delivery characteristics of Bricanyl TurbohalerTM dry powder inhalers. Int J Pharm. 1995;119:91–102(1).
   Google Scholar
• Hillery AM, Lloyd AW, Swarbrick J. Pulmonary drug delivery. Drug delivery and targeting for pharmacists and pharmaceutical scientists. London: Taylor & Francis; 2001. p. 269–300.
   Google Scholar